Latest Pharma Insights
Early Safety Data Show ProMIS May Have A Differentiated Anti-Amyloid Drug
Interim Phase Ib data for PMN310 show no cases of amyloid-related imaging abnormalities with edema (ARIA-E), a safety risk associated with approved drugs that requires repeat MRI monitoring.
Scrip - July 28, 2026
Interim Phase Ib data for PMN310 show no cases of amyloid-related imaging abnormalities with edema (ARIA-E), a safety risk associated with approved drugs that requires repeat MRI monitoring.
Scrip - July 28, 2026
UK Bets On Quantum Medtech With New Investments
£1.65m NIHR funding for early-stage quantum medical devices follows wider £2bn government drive.
Medtech Insight - July 28, 2026
£1.65m NIHR funding for early-stage quantum medical devices follows wider £2bn government drive.
Medtech Insight - July 28, 2026
J&J Proposes $5.5Bn Settlement In Ovarian Talc Litigation
Johnson & Johnson has reached a $5.5bn settlement over its talc-containing products, though it is contingent upon broad plaintiff participation.
HBW Insight - July 28, 2026
Johnson & Johnson has reached a $5.5bn settlement over its talc-containing products, though it is contingent upon broad plaintiff participation.
HBW Insight - July 28, 2026
Tylenol With Naproxen Plus Market Exclusivity Added To Kenvue’s Kimberly-Clark Basket
Kenvue receives market exclusivity with FDA approval of Tylenol with Naproxen. It positions formulation not only as additional option for consumers’ OTC supplies, but also a tool in helping curb opioids abuse.
HBW Insight - July 28, 2026
Kenvue receives market exclusivity with FDA approval of Tylenol with Naproxen. It positions formulation not only as additional option for consumers’ OTC supplies, but also a tool in helping curb opioids abuse.
HBW Insight - July 28, 2026
Altimmune Scores Alcohol Use Disorder Win As Lilly, Novo Circle Same Indication
Moving into Phase III in MASH, Altimmune's new Phase II results suggest pemvidutide may also offer commercial potential in AUD, which has several lightly utilized approved therapies but is also being targeted by Lilly and Novo Nordisk.
Scrip - July 28, 2026
Moving into Phase III in MASH, Altimmune's new Phase II results suggest pemvidutide may also offer commercial potential in AUD, which has several lightly utilized approved therapies but is also being targeted by Lilly and Novo Nordisk.
Scrip - July 28, 2026
Atea Touts Drug Interaction Profile, Shorter Treatment In Taking On Hepatitis C Giants
The company announced topline results for BEM/RZR, which offers an eight-week treatment duration, no food requirements and a favorable drug-drug interaction profile.
Scrip - July 28, 2026
The company announced topline results for BEM/RZR, which offers an eight-week treatment duration, no food requirements and a favorable drug-drug interaction profile.
Scrip - July 28, 2026
FDA Reminder: File MDUFA Small-Business Application By Aug. 1
Device companies have until 4 p.m. Eastern time Aug. 1 to apply for an MDUFA small-business designation for FY 2026 — the first year the FDA has enforced the earlier cutoff, which previously fell on Sept. 30.
Medtech Insight - July 28, 2026
Device companies have until 4 p.m. Eastern time Aug. 1 to apply for an MDUFA small-business designation for FY 2026 — the first year the FDA has enforced the earlier cutoff, which previously fell on Sept. 30.
Medtech Insight - July 28, 2026
Incyte’s Opzelura Poised To Cross $1bn In Sales
The company raised financial guidance for the topical dermatology medicine based on a positive reimbursement development with the US government and an uptick in sales.
Scrip - July 28, 2026
The company raised financial guidance for the topical dermatology medicine based on a positive reimbursement development with the US government and an uptick in sales.
Scrip - July 28, 2026
Why SynAct Thinks Resomelagon’s Two Phase II Misses Are A Design Problem, Not A Drug Problem
The efficacy signal has been consistently positive across studies. The problem is a placebo response that keeps outrunning the study design
In Vivo - July 28, 2026
The efficacy signal has been consistently positive across studies. The problem is a placebo response that keeps outrunning the study design
In Vivo - July 28, 2026
Abbott Launches Post-Market Study of TriClip in Real-World Patients
Abbott has launched a post-market study to gauge the safety and real-world performance of its TriClip transcatheter edge-to-edge repair system for treating tricuspid regurgitation. The five-year study will enroll some 1,000 patients across 100 sites in North America and Europe.
Medtech Insight - July 28, 2026
Abbott has launched a post-market study to gauge the safety and real-world performance of its TriClip transcatheter edge-to-edge repair system for treating tricuspid regurgitation. The five-year study will enroll some 1,000 patients across 100 sites in North America and Europe.
Medtech Insight - July 28, 2026
As Blockbusters Genericize, Precision Bets Reshape The Autoimmune Pipeline
Precision medicine is coming to autoimmune diseases. Investors and dealmakers are buying in to more powerful, safer treatment prospects in large markets.
In Vivo - July 28, 2026
Precision medicine is coming to autoimmune diseases. Investors and dealmakers are buying in to more powerful, safer treatment prospects in large markets.
In Vivo - July 28, 2026
Gossamer’s Seralutinib NDA Plans Intact After FDA Clears Filing Path
After months of regulatory uncertainty following its Phase III PROSERA study's missed statistical threshold, the FDA's feedback on seralutinib is a shot in the arm for Gossamer.
Scrip - July 28, 2026
After months of regulatory uncertainty following its Phase III PROSERA study's missed statistical threshold, the FDA's feedback on seralutinib is a shot in the arm for Gossamer.
Scrip - July 28, 2026
GSK Cuts Costs With Phase III Starts Set To Double
The company now expects over 20 late-stage trials to begin this year and is targeting annual cost savings of £1.9bn to pay for them.
Scrip - July 28, 2026
The company now expects over 20 late-stage trials to begin this year and is targeting annual cost savings of £1.9bn to pay for them.
Scrip - July 28, 2026
Sarepta Taps Outsider CEO As Exon-Skippers Face Key Test
Sarepta has named former AbbVie R&D leader Michael Severino CEO ahead of a crucial FDA decision on whether failed confirmatory trials will cost Amondys 45 and Vyondys 53 their accelerated approval status.
Scrip - July 28, 2026
Sarepta has named former AbbVie R&D leader Michael Severino CEO ahead of a crucial FDA decision on whether failed confirmatory trials will cost Amondys 45 and Vyondys 53 their accelerated approval status.
Scrip - July 28, 2026
As Tech Stocks Tumble, AstraZeneca Reins In AI Spending
A long-awaited sell-off of AI company stocks has arrived; is this also a wake-up call for big pharma’s spending spree on the technology?
Scrip - July 28, 2026
A long-awaited sell-off of AI company stocks has arrived; is this also a wake-up call for big pharma’s spending spree on the technology?
Scrip - July 28, 2026
As Cipla Chases US Milestone, Generic Ventolin Scale-up Is Key
Cipla's $1bn US revenue target by end-FY27 hinges on a handful of high-stakes bets — generic Ventolin scaling quickly and approvals for products like generic Advair and a peptide which it sees as a significant opportunity.
Generics Bulletin - July 28, 2026
Cipla's $1bn US revenue target by end-FY27 hinges on a handful of high-stakes bets — generic Ventolin scaling quickly and approvals for products like generic Advair and a peptide which it sees as a significant opportunity.
Generics Bulletin - July 28, 2026
Merck Signs License Agreements For Monthly PrEP Drug Alimatravir In Developing Countries
The company reached agreements with generic drugmakers to supply the drug in 129 low- and middle-income countries that account for a significant share of global HIV burden.
Generics Bulletin - July 28, 2026
The company reached agreements with generic drugmakers to supply the drug in 129 low- and middle-income countries that account for a significant share of global HIV burden.
Generics Bulletin - July 28, 2026
Stock Watch: Why Novartis Stock Rose On Results Half As Good As J&J’s
Novartis grew sales at less than half J&J's rate in Q2, yet investors reacted more warmly — a result explained less by the numbers than the residual of Entresto's sales left to erode.
Scrip - July 28, 2026
Novartis grew sales at less than half J&J's rate in Q2, yet investors reacted more warmly — a result explained less by the numbers than the residual of Entresto's sales left to erode.
Scrip - July 28, 2026
Late To The Party: Can Cipla’s Generic Advair Catch Up In The US Market?
Cipla is set to enter the multi-player generic Advair race in the US, but market dynamics appear to have tempered revenue expectations. Can the Indian firm carve out a meaningful slice of the market?
Scrip - July 28, 2026
Cipla is set to enter the multi-player generic Advair race in the US, but market dynamics appear to have tempered revenue expectations. Can the Indian firm carve out a meaningful slice of the market?
Scrip - July 28, 2026
FDA Approves Amneal’s Generic Omnipaque With Four New Iohexol Presentations
The US FDA has approved Amneal’s Iohexol, a radiographic contrast agent that a mere few months ago was facing reported product shortages.
Generics Bulletin - July 28, 2026
The US FDA has approved Amneal’s Iohexol, a radiographic contrast agent that a mere few months ago was facing reported product shortages.
Generics Bulletin - July 28, 2026
Sun Opens Up South African GLP-1 Competition With Semaglutide Launch
Sun has confirmed the launch of its generic semaglutide for diabetes in South Africa, just a couple of weeks after receiving approval.
Generics Bulletin - July 28, 2026
Sun has confirmed the launch of its generic semaglutide for diabetes in South Africa, just a couple of weeks after receiving approval.
Generics Bulletin - July 28, 2026
Brexit Mutual Recognition Loss Still Raises Costs For UK Generics Manufacturers, Conference Hears
At Medicines UK’s annual London conference, experts discussed how industry is working to secure the UK’s medicines future, especially when it comes to the lasting impacts created by the 2016 Brexit referendum, in which the country voted to leave the European Union.
Generics Bulletin - July 28, 2026
At Medicines UK’s annual London conference, experts discussed how industry is working to secure the UK’s medicines future, especially when it comes to the lasting impacts created by the 2016 Brexit referendum, in which the country voted to leave the European Union.
Generics Bulletin - July 28, 2026
Cipla Joins Generic Advair Club With FDA Approval
Cipla has delivered on its filing for a US Advair generic, garnering a long-sought FDA approval. But with several other players in the US market, the dynamic will be crowded.
Generics Bulletin - July 28, 2026
Cipla has delivered on its filing for a US Advair generic, garnering a long-sought FDA approval. But with several other players in the US market, the dynamic will be crowded.
Generics Bulletin - July 28, 2026
Accord’s Late Launch Still Raises Stakes In Denosumab Battle
Accord has launched interchangeable Prolia and Xgeva biosimilars Osvyrti and Jubereq in the US, entering a crowded denosumab market with Cigna formulary support, patient assistance and pricing designed to challenge Amgen’s established brands.
Generics Bulletin - July 28, 2026
Accord has launched interchangeable Prolia and Xgeva biosimilars Osvyrti and Jubereq in the US, entering a crowded denosumab market with Cigna formulary support, patient assistance and pricing designed to challenge Amgen’s established brands.
Generics Bulletin - July 28, 2026
CSPC’s Novel Antidepressant Hits Mark In First-Line China Phase III Trial
CSPC's ammoxetine beats placebo and was numerically superior to Zoloft in a Chinese Phase III trial for the first-line treatment of depression.
Scrip - July 28, 2026
CSPC's ammoxetine beats placebo and was numerically superior to Zoloft in a Chinese Phase III trial for the first-line treatment of depression.
Scrip - July 28, 2026
Chugai Fortifies Investment Function Amid Successful H1
After establishing multiple investment arms globally, the major Japanese firm has set up a new Tokyo-based team to potentially direct a portion of growing revenues into M&As and other transactions.
Scrip - July 28, 2026
After establishing multiple investment arms globally, the major Japanese firm has set up a new Tokyo-based team to potentially direct a portion of growing revenues into M&As and other transactions.
Scrip - July 28, 2026
The Generics Bulletin Top 50, Part Two: Fresh Data Shakes Up Mid-Table Players
In the second part of this year’s Generics Bulletin Top 50, we see Apotex join our rankings for the first time, after the company released detailed financial data as part of its recent IPO. How will this shake up our middle table?
Generics Bulletin - July 28, 2026
In the second part of this year’s Generics Bulletin Top 50, we see Apotex join our rankings for the first time, after the company released detailed financial data as part of its recent IPO. How will this shake up our middle table?
Generics Bulletin - July 28, 2026
Beauty Brand ‘AI Visibility’ Shaped by Editorial Media, Retailers
AI is reshaping beauty discovery, with brands gaining visibility by building authority across editorial media, retailer ecosystems and other third-party sources that influence how AI platforms generate recommendations.
HBW Insight - July 28, 2026
AI is reshaping beauty discovery, with brands gaining visibility by building authority across editorial media, retailer ecosystems and other third-party sources that influence how AI platforms generate recommendations.
HBW Insight - July 28, 2026
Early Safety Data Show ProMIS May Have A Differentiated Anti-Amyloid Drug
Interim Phase Ib data for PMN310 show no cases of amyloid-related imaging abnormalities with edema (ARIA-E), a safety risk associated with approved drugs that requires repeat MRI monitoring.
Scrip - July 28, 2026
Interim Phase Ib data for PMN310 show no cases of amyloid-related imaging abnormalities with edema (ARIA-E), a safety risk associated with approved drugs that requires repeat MRI monitoring.
Scrip - July 28, 2026
Altimmune Scores Alcohol Use Disorder Win As Lilly, Novo Circle Same Indication
Moving into Phase III in MASH, Altimmune's new Phase II results suggest pemvidutide may also offer commercial potential in AUD, which has several lightly utilized approved therapies but is also being targeted by Lilly and Novo Nordisk.
Scrip - July 28, 2026
Moving into Phase III in MASH, Altimmune's new Phase II results suggest pemvidutide may also offer commercial potential in AUD, which has several lightly utilized approved therapies but is also being targeted by Lilly and Novo Nordisk.
Scrip - July 28, 2026
Atea Touts Drug Interaction Profile, Shorter Treatment In Taking On Hepatitis C Giants
The company announced topline results for BEM/RZR, which offers an eight-week treatment duration, no food requirements and a favorable drug-drug interaction profile.
Scrip - July 28, 2026
The company announced topline results for BEM/RZR, which offers an eight-week treatment duration, no food requirements and a favorable drug-drug interaction profile.
Scrip - July 28, 2026
Incyte’s Opzelura Poised To Cross $1bn In Sales
The company raised financial guidance for the topical dermatology medicine based on a positive reimbursement development with the US government and an uptick in sales.
Scrip - July 28, 2026
The company raised financial guidance for the topical dermatology medicine based on a positive reimbursement development with the US government and an uptick in sales.
Scrip - July 28, 2026
Gossamer’s Seralutinib NDA Plans Intact After FDA Clears Filing Path
After months of regulatory uncertainty following its Phase III PROSERA study's missed statistical threshold, the FDA's feedback on seralutinib is a shot in the arm for Gossamer.
Scrip - July 28, 2026
After months of regulatory uncertainty following its Phase III PROSERA study's missed statistical threshold, the FDA's feedback on seralutinib is a shot in the arm for Gossamer.
Scrip - July 28, 2026
GSK Cuts Costs With Phase III Starts Set To Double
The company now expects over 20 late-stage trials to begin this year and is targeting annual cost savings of £1.9bn to pay for them.
Scrip - July 28, 2026
The company now expects over 20 late-stage trials to begin this year and is targeting annual cost savings of £1.9bn to pay for them.
Scrip - July 28, 2026
Sarepta Taps Outsider CEO As Exon-Skippers Face Key Test
Sarepta has named former AbbVie R&D leader Michael Severino CEO ahead of a crucial FDA decision on whether failed confirmatory trials will cost Amondys 45 and Vyondys 53 their accelerated approval status.
Scrip - July 28, 2026
Sarepta has named former AbbVie R&D leader Michael Severino CEO ahead of a crucial FDA decision on whether failed confirmatory trials will cost Amondys 45 and Vyondys 53 their accelerated approval status.
Scrip - July 28, 2026
As Tech Stocks Tumble, AstraZeneca Reins In AI Spending
A long-awaited sell-off of AI company stocks has arrived; is this also a wake-up call for big pharma’s spending spree on the technology?
Scrip - July 28, 2026
A long-awaited sell-off of AI company stocks has arrived; is this also a wake-up call for big pharma’s spending spree on the technology?
Scrip - July 28, 2026
Stock Watch: Why Novartis Stock Rose On Results Half As Good As J&J’s
Novartis grew sales at less than half J&J's rate in Q2, yet investors reacted more warmly — a result explained less by the numbers than the residual of Entresto's sales left to erode.
Scrip - July 28, 2026
Novartis grew sales at less than half J&J's rate in Q2, yet investors reacted more warmly — a result explained less by the numbers than the residual of Entresto's sales left to erode.
Scrip - July 28, 2026
Late To The Party: Can Cipla’s Generic Advair Catch Up In The US Market?
Cipla is set to enter the multi-player generic Advair race in the US, but market dynamics appear to have tempered revenue expectations. Can the Indian firm carve out a meaningful slice of the market?
Scrip - July 28, 2026
Cipla is set to enter the multi-player generic Advair race in the US, but market dynamics appear to have tempered revenue expectations. Can the Indian firm carve out a meaningful slice of the market?
Scrip - July 28, 2026
CSPC’s Novel Antidepressant Hits Mark In First-Line China Phase III Trial
CSPC's ammoxetine beats placebo and was numerically superior to Zoloft in a Chinese Phase III trial for the first-line treatment of depression.
Scrip - July 28, 2026
CSPC's ammoxetine beats placebo and was numerically superior to Zoloft in a Chinese Phase III trial for the first-line treatment of depression.
Scrip - July 28, 2026
Chugai Fortifies Investment Function Amid Successful H1
After establishing multiple investment arms globally, the major Japanese firm has set up a new Tokyo-based team to potentially direct a portion of growing revenues into M&As and other transactions.
Scrip - July 28, 2026
After establishing multiple investment arms globally, the major Japanese firm has set up a new Tokyo-based team to potentially direct a portion of growing revenues into M&As and other transactions.
Scrip - July 28, 2026
UK Bets On Quantum Medtech With New Investments
£1.65m NIHR funding for early-stage quantum medical devices follows wider £2bn government drive.
Medtech Insight - July 28, 2026
£1.65m NIHR funding for early-stage quantum medical devices follows wider £2bn government drive.
Medtech Insight - July 28, 2026
FDA Reminder: File MDUFA Small-Business Application By Aug. 1
Device companies have until 4 p.m. Eastern time Aug. 1 to apply for an MDUFA small-business designation for FY 2026 — the first year the FDA has enforced the earlier cutoff, which previously fell on Sept. 30.
Medtech Insight - July 28, 2026
Device companies have until 4 p.m. Eastern time Aug. 1 to apply for an MDUFA small-business designation for FY 2026 — the first year the FDA has enforced the earlier cutoff, which previously fell on Sept. 30.
Medtech Insight - July 28, 2026
Abbott Launches Post-Market Study of TriClip in Real-World Patients
Abbott has launched a post-market study to gauge the safety and real-world performance of its TriClip transcatheter edge-to-edge repair system for treating tricuspid regurgitation. The five-year study will enroll some 1,000 patients across 100 sites in North America and Europe.
Medtech Insight - July 28, 2026
Abbott has launched a post-market study to gauge the safety and real-world performance of its TriClip transcatheter edge-to-edge repair system for treating tricuspid regurgitation. The five-year study will enroll some 1,000 patients across 100 sites in North America and Europe.
Medtech Insight - July 28, 2026
J&J Proposes $5.5Bn Settlement In Ovarian Talc Litigation
Johnson & Johnson has reached a $5.5bn settlement over its talc-containing products, though it is contingent upon broad plaintiff participation.
HBW Insight - July 28, 2026
Johnson & Johnson has reached a $5.5bn settlement over its talc-containing products, though it is contingent upon broad plaintiff participation.
HBW Insight - July 28, 2026
Tylenol With Naproxen Plus Market Exclusivity Added To Kenvue’s Kimberly-Clark Basket
Kenvue receives market exclusivity with FDA approval of Tylenol with Naproxen. It positions formulation not only as additional option for consumers’ OTC supplies, but also a tool in helping curb opioids abuse.
HBW Insight - July 28, 2026
Kenvue receives market exclusivity with FDA approval of Tylenol with Naproxen. It positions formulation not only as additional option for consumers’ OTC supplies, but also a tool in helping curb opioids abuse.
HBW Insight - July 28, 2026
Beauty Brand ‘AI Visibility’ Shaped by Editorial Media, Retailers
AI is reshaping beauty discovery, with brands gaining visibility by building authority across editorial media, retailer ecosystems and other third-party sources that influence how AI platforms generate recommendations.
HBW Insight - July 28, 2026
AI is reshaping beauty discovery, with brands gaining visibility by building authority across editorial media, retailer ecosystems and other third-party sources that influence how AI platforms generate recommendations.
HBW Insight - July 28, 2026
As Cipla Chases US Milestone, Generic Ventolin Scale-up Is Key
Cipla's $1bn US revenue target by end-FY27 hinges on a handful of high-stakes bets — generic Ventolin scaling quickly and approvals for products like generic Advair and a peptide which it sees as a significant opportunity.
Generics Bulletin - July 28, 2026
Cipla's $1bn US revenue target by end-FY27 hinges on a handful of high-stakes bets — generic Ventolin scaling quickly and approvals for products like generic Advair and a peptide which it sees as a significant opportunity.
Generics Bulletin - July 28, 2026
Merck Signs License Agreements For Monthly PrEP Drug Alimatravir In Developing Countries
The company reached agreements with generic drugmakers to supply the drug in 129 low- and middle-income countries that account for a significant share of global HIV burden.
Generics Bulletin - July 28, 2026
The company reached agreements with generic drugmakers to supply the drug in 129 low- and middle-income countries that account for a significant share of global HIV burden.
Generics Bulletin - July 28, 2026
FDA Approves Amneal’s Generic Omnipaque With Four New Iohexol Presentations
The US FDA has approved Amneal’s Iohexol, a radiographic contrast agent that a mere few months ago was facing reported product shortages.
Generics Bulletin - July 28, 2026
The US FDA has approved Amneal’s Iohexol, a radiographic contrast agent that a mere few months ago was facing reported product shortages.
Generics Bulletin - July 28, 2026
Sun Opens Up South African GLP-1 Competition With Semaglutide Launch
Sun has confirmed the launch of its generic semaglutide for diabetes in South Africa, just a couple of weeks after receiving approval.
Generics Bulletin - July 28, 2026
Sun has confirmed the launch of its generic semaglutide for diabetes in South Africa, just a couple of weeks after receiving approval.
Generics Bulletin - July 28, 2026
Brexit Mutual Recognition Loss Still Raises Costs For UK Generics Manufacturers, Conference Hears
At Medicines UK’s annual London conference, experts discussed how industry is working to secure the UK’s medicines future, especially when it comes to the lasting impacts created by the 2016 Brexit referendum, in which the country voted to leave the European Union.
Generics Bulletin - July 28, 2026
At Medicines UK’s annual London conference, experts discussed how industry is working to secure the UK’s medicines future, especially when it comes to the lasting impacts created by the 2016 Brexit referendum, in which the country voted to leave the European Union.
Generics Bulletin - July 28, 2026
Cipla Joins Generic Advair Club With FDA Approval
Cipla has delivered on its filing for a US Advair generic, garnering a long-sought FDA approval. But with several other players in the US market, the dynamic will be crowded.
Generics Bulletin - July 28, 2026
Cipla has delivered on its filing for a US Advair generic, garnering a long-sought FDA approval. But with several other players in the US market, the dynamic will be crowded.
Generics Bulletin - July 28, 2026
Accord’s Late Launch Still Raises Stakes In Denosumab Battle
Accord has launched interchangeable Prolia and Xgeva biosimilars Osvyrti and Jubereq in the US, entering a crowded denosumab market with Cigna formulary support, patient assistance and pricing designed to challenge Amgen’s established brands.
Generics Bulletin - July 28, 2026
Accord has launched interchangeable Prolia and Xgeva biosimilars Osvyrti and Jubereq in the US, entering a crowded denosumab market with Cigna formulary support, patient assistance and pricing designed to challenge Amgen’s established brands.
Generics Bulletin - July 28, 2026
The Generics Bulletin Top 50, Part Two: Fresh Data Shakes Up Mid-Table Players
In the second part of this year’s Generics Bulletin Top 50, we see Apotex join our rankings for the first time, after the company released detailed financial data as part of its recent IPO. How will this shake up our middle table?
Generics Bulletin - July 28, 2026
In the second part of this year’s Generics Bulletin Top 50, we see Apotex join our rankings for the first time, after the company released detailed financial data as part of its recent IPO. How will this shake up our middle table?
Generics Bulletin - July 28, 2026
Why SynAct Thinks Resomelagon’s Two Phase II Misses Are A Design Problem, Not A Drug Problem
The efficacy signal has been consistently positive across studies. The problem is a placebo response that keeps outrunning the study design
In Vivo - July 28, 2026
The efficacy signal has been consistently positive across studies. The problem is a placebo response that keeps outrunning the study design
In Vivo - July 28, 2026
As Blockbusters Genericize, Precision Bets Reshape The Autoimmune Pipeline
Precision medicine is coming to autoimmune diseases. Investors and dealmakers are buying in to more powerful, safer treatment prospects in large markets.
In Vivo - July 28, 2026
Precision medicine is coming to autoimmune diseases. Investors and dealmakers are buying in to more powerful, safer treatment prospects in large markets.
In Vivo - July 28, 2026